Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798834 | 0.96 | DRD2 (0.36) | DRD2SIGMAR1KDM4EMAPTNPSR1 | |
| SCHEMBL6790817 | 0.88 | DRD2 (0.35) | DRD2SIGMAR1KDM4EMAPTNPSR1 | |
| SCHEMBL6794681 | 0.87 | DRD2 (0.38) | DRD2SIGMAR1CKS1BSKP1SKP2 | |
| SCHEMBL6793099 | 0.85 | LMNA (0.36) | KDM4EMAPTKCNA3 | |
| SCHEMBL6798581 | 0.84 | OPRM1 (0.33) | KDM4EMAPTKCNA3 | |
| SCHEMBL6790712 | 0.83 | P2RY12 (0.34) | KDM4EMAPT | |
| SCHEMBL6793129 | 0.82 | MEN1 (0.39) | KDM4EMAPT | |
| SCHEMBL6794835 | 0.81 | OPRD1 (0.35) | KDM4EMAPTKCNA3 | |
| SCHEMBL6791964 | 0.79 | KDM4E (0.35) | DRD2SIGMAR1KDM4EMAPTNPSR1 | |
| SCHEMBL6798838 | 0.75 | ADORA1 (0.35) | DRD2SIGMAR1KDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DRD2 4396/4885SIGMAR1 4084/4885KDM4E 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.